Skip to main content

Anti-hypertensive medications

Anti-hypertensive medications

13-10-2022 | Anti-hypertensive medications | News

TIME of antihypertensive administration ‘should be shared decision’

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.

Doctor measuring arterial blood pressure on arm of a patient

28-07-2022 | Anti-hypertensive medications | News

No justification for bespoke antihypertensive intervention in type 2 diabetes

The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.

White electric tonometer indicating blood pressure and pills on black background

03-03-2022 | Anti-hypertensive medications | News

Verapamil type 1 diabetes benefits sustained for at least 2 years

Researchers report that the antihypertensive medication verapamil preserves beta-cell function and reduces insulin needs in adults with type 1 diabetes during up to 2 years of treatment.

Person having blood pressure checked

17-11-2021 | Diabetes prevention | News

Lowering blood pressure may help type 2 diabetes prevention

Reducing blood pressure may be an effective strategy for the prevention of new-onset type 2 diabetes, suggest researchers from the Blood Pressure Lowering Treatment Trialists’ Collaboration.

Glucose monitor, heart, and stethoscope

26-09-2020 | EASD 2020 | Conference coverage | News

Cardioprotective measures neglected in young-onset type 2 diabetes

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

24-10-2019 | Hypertension | News

Bedtime hypertension medication best for averting CV events

A large randomized trial may have settled the question of whether it is best to take blood pressure medications in the morning or evening.

Kidneys

20-09-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

Luigi Gnudi

20-09-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial results

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

Jay Shubrook, Katherine Tuttle

13-04-2019 | Nephropathy | Video | Article

Diabetic kidney disease: A call to primary care

Nephrologist and Endocrinologist Katherine Tuttle joins Primary Care Physician Jay Shubrook to share best practice tips for kidney disease screening in patients with diabetes (8:16).

05-12-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

Files

30-09-2018 | UKPDS | At a glance | Article

What we learned from the UKPDS

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

18-04-2018 | Nephropathy | News

Neprilysin inhibition appears beneficial in diabetic kidney disease

Secondary analysis of the PARADIGM-HF trial shows that the adverse effects of diabetes on kidney function can be ameliorated by a neprilysin inhibitor.

In the wake of the revised blood pressure targets, recommended by the American Diabetes Association's 2017 Position Statement and 2018 Standards of Care, Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton discuss clinical approaches to get hypertensive diabetes patients to target more consistently (12:29).


Learning points include:

  • The atherogenic risk posed by diabetes and why blood pressure measurements from the arm-alone may not be sufficient to evaluate the threat in all patients.
  • The benefits and drawbacks of the medication classes indicated for hypertension treatment, such as:
    • Diuretics
    • β-blockers
    • Calcium channel blockers
  • The impact and rationale for targeting blood pressures lower than those indicated in the ADA position statement. 

« Video 2: What are the current recommendations for managing high blood pressure in diabetes patients?



Video 3: When to intervene in patients with diabetes and high blood pressure? »

28-01-2018 | Cardiovascular disorders | Review | Article

Blood pressure targets in type 2 diabetes. Evidence against or in favor of an aggressive approach

Mancia G, Grassi G. Diabetologia 2018; 61: 517–525. doi: 10.1007/s00125-017-4537-3

05-02-2018 | Cardiovascular disorders | Review | Article

Type 2 diabetes and thiazide diuretics

Scheen AJ. Curr Diab Rep 2018; 18: 6. doi: 10.1007/s11892-018-0976-6

05-01-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3